MDK and hepatocellular carcinoma: Following lysosomal drug release, MDK-siRNA is anticipated to neutralize the immunosuppressive TME by modulating both M2 TAMs and MDSCs, thereby augmenting ICB efficacy in HCC immunotherapy in conjunction with aPD-1.